Core Viewpoint - The company has successfully administered the first dose of its self-developed radiolabeled drug, 177Lu-PSMA-3D1015 (3D1015), to a patient, marking a significant milestone in its clinical research for treating PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) [1] Group 1: Clinical Research Focus - The study specifically targets patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) [1] - The research will systematically evaluate the core clinical value of 3D1015, focusing on the drug's safety and radiation dosimetry assessment [1] - The study aims to collect in-depth pharmacokinetic characteristics and dose exploration data of the drug in humans, providing direct clinical evidence for dose determination and risk control in subsequent registration clinical trials [1]

Core Viewpoint - The company has successfully administered its first self-developed radiopharmaceutical drug, 177Lu-PSMA-3D1015 (3D1015), to a patient, marking a significant milestone in its clinical research for treating PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) [1] Group 1: Clinical Research - The study focuses on evaluating the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive mCRPC [1] - The research aims to systematically assess the core clinical value of 3D1015, emphasizing drug safety and dosimetry evaluation [1] - The study will collect in-depth pharmacokinetic characteristics and dose exploration data to provide direct clinical evidence for dose determination and risk control in subsequent registration clinical trials [1]

金十数据4月21日讯，远大医药公告称，集团合作开发的用于诊断肝细胞癌（HCC）的全球创新放射性 核素偶联药物(RDC) GPN02006，在中国开展的研究者发起的临床研究（IIT临床研究），近日取得了里 程碑式突破，并于成都2025未来XDC新药大会中公开发表了临床结果。此次研究进展，标志着集团在 抗肿瘤核药研发领域再次取得重大突破，GPN02006有望成为全球首个针对GPC-3靶点的HCC诊断类 RDC产品。 远大医药：全球创新RDC药物GPN02006研发迎来新突破 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號：00512) 自願性公告 董事會欣然公告，本集團與武漢睿迪輻生物科技有限公司、傑科（天津）生物醫藥有 限公司合作開發的用於診斷肝細胞癌（hepatocellular carcinoma，HCC）的全球創新 放射性核素偶聯藥物「( RDC」) GPN02006 在中國開展的研究者發起的臨床研究（IIT 臨床研究），近日取得了里程碑式突破，並於成都 2025 未來 XDC 新藥大會中公開 發表了臨床結果。該研究是一項前瞻性、單中心、診斷性的臨床研究，在超過 80 例 臨床懷疑或者確診的 HCC 患者中，使用 GPN02006 並進行正電子發射斷層成像/電 腦斷層掃描（PET/CT）或正電子發射斷層成像/磁共振成像（PET/MRI）顯像，以初 步評估該產品對 HCC 的診 ...